12/15/2015
Line-associated DVT, Calf Vein DVT and Superficial Vein Thrombosis: What to do. Ian Del Conde, MD, FACC Vascular Medicine and Cardiology Miami Cardiac and Vascular Institute HeartWell December 12, 2015
Disclosures CONSULTANT Merck; New Haven Pharmaceuticals ADVISORY BOARD Merck, IC Sciences SPEAKER’S BUREAU Johnson & Johnson, BMS, Pfizer
1
12/15/2015
1. Line-associated DVT 2. Calf Vein DVT 3. Superficial Vein Thrombosis
Line-Associated DVT
PICC line
Hemodialysis Catheters And P-A-C
PPM/AICD
2
12/15/2015
Venous Anatomy of the Upper Extremity DEEP VEINS Brachiocephalic V. Jugular V. Subclavian V. Axillary V.
Distal
Proximal
Anticoagulation
Anticoagulation may not be necessary
Brachial V. Ulnar V. Radial V. SUPERFICIAL VEINS Cephalic V. Basilic V.
Line-Associated Venous Thrombosis: Epidemiology Overview • 50-60% of all cases of UEDVT are lineassociated. • Two-thirds are asymptomatic • Risk factors: – – – – –
Active cancer Radiation therapy, chemo, TPN Catheter tip not at atriocaval junct Catheter size (AICD/CRT) Prior central venous catheterization The DVT FREE Steering Committee. Circulation. 2004; 110: 1605-1611
3
12/15/2015
Symptoms and Physical Exam Symptoms: discomfort, pain, paresthesias, discoloration, swelling
Symptoms and Physical Exam Symptoms: discomfort, pain, paresthesias, discoloration, swelling
4
12/15/2015
Symptoms and Physical Exam Symptoms: discomfort, pain, paresthesias, discoloration, swelling
Questions to Address: Patient Factors 1. What vein segment is involved? 2. Is proximal extension likely? 3. Any indication of SVC syndrome? 4. Contraindication to anticoagulation?
5
12/15/2015
Questions to Address: Catheter Factors 1. Is the catheter still needed? (IV meds, blood draws, TPN, etc.)
2. Is the catheter functional? 3. Any evidence of infection?
Management of Catheter Associated UE DVT Routine catheter removal is generally not recommended • Difficult access, continued need for further IV access should be considered • Must be able to anticoagulate the patient
Removal is warranted in: • Malfunctioning catheter, infection, contraindication to anticoagulation, persistent signs and symptoms despite treatment.
6
12/15/2015
What do the Guidelines Say? • Anticoagulate for as long as the catheter remains in place. • If the catheter is removed, and the DVT involves the axillary or subclavian veins, anticoagulate for 3 months (longer if the patient has cancer).
Calf Vein Thrombosis Opinions differ: • Need to examine calf veins? • Need to treat?
7
12/15/2015
Veins of the Calf DEEP VEINS Anterior tibial V. Posterior tibial V. Peroneal V.
MUSCULAR VEINS Gastrocnemius V Soleal V.
SUPERFICIAL VEINS Greater saphenous V. Short saphenous V.
Observations: • With no treatment, 15% propagate to popliteal vein. • Pulmonary embolism rarely occurs ( 7 mm in diameter
2012 ACCP Guidelines
Calf Vein Thrombosis: Bottom Line • Who to treat with anticoagulation? • Symptomatic patients • Risk factors for extension • Full-dose anticoagulation, (same as for prox. DVT)
• • • •
Extensive > 2 veins Close to prox. veins > 7 mm in diameter
• If anticoagulation is not prescribed, serial duplex ultrasounds for 2 weeks. 2012 ACCP Guidelines
10
12/15/2015
34F, otherwise healthy. Acute R leg pain during a basketball game. Swollen, painful leg. Venous duplex: Acute thrombosis of the gastrocnemius vein.
Scimitar sign
Should this patient be anticoagulated?
Gastrocnemius Tear
No anticoagulation!! Repeat duplex US in 1 week.
11
12/15/2015
Superficial Vein Thrombosis
Common Femoral V. Femoral V.
Peroneal V. Ant. Tibial V.
Greater Saphenous V. (GSV) Small Saphenous V. (SSV)
Dorsal Venous arch.
12
12/15/2015
Common Femoral V. Femoral V.
Peroneal V. Ant. Tibial V.
CFV
Greater Saphenous V. (GSV) Small Saphenous V. (SSV)
GSV
CFV
FV
Dorsal Venous arch.
Common Femoral V. Femoral V.
Peroneal V. Ant. Tibial V.
Greater Saphenous V. (GSV) Small Saphenous V. (SSV)
GSV Thrombus
Dorsal Venous arch.
13
12/15/2015
Common Femoral V. Femoral V.
Peroneal V. Ant. Tibial V.
Greater Saphenous V. (GSV) Small Saphenous V. (SSV)
Dorsal Venous arch.
Risk Factors for Superficial V. Thrombosis Varicose veins
82%
Prior DVT/PE
22%
Cancer
6%
Immobility
8%
Recent Hospitalization
9%
Surgery
4%
Trauma
5%
Hormone
13% Ann Intern Med 2010;152:218
14
12/15/2015
What is the incidence of DVT/PE in Patients with SVT? 844 patients • Whole leg Duplex US Proximal DVT
10%
Calf DVT
14%
PE
4%
Total VTE = 25% Ann Intern Med 2010;152:218
SVT Epidemiology: Bottom Line • 1 in 4 patients will have DVT/PE US imaging in for all SVT patients CTA in selected patients
•With isolated SVT, VTE rates low @ 3 months: DVT 3% PE 0.5%
•Risk factors for VTE complications : Male gender, prior VTE, cancer, no varicosities
15
12/15/2015
How should patients with isolated Superficial Vein Thrombosis be treated?
Arixtra for SVT Treatment CALISTO Trial
1º endpoint: death, DVT/PE, SVT extension into SFJ @ 11 wks NEJM 2010;363:1222
16
12/15/2015
CALISTO Trial Placebo
Fondaparinux (Arixtra)
NEJM 2010;363:1222
1º endpoint: 1.2% vs. 6.3%; NNT = 20 (death, DVT/PE, SVT extension into SFJ @ 11 weeks)
SVT Treatment: Bottom Line • With isolated SVT, VTE rates low @ 3 months • Who to treat? • Severe symptoms • Great saphenous vein involvement (vs. tributary) • Long segment (> 5 cm) • Proximity to saphenofemoral junction (5 cm) • SVT extension/propagation • Risk factors for VTE complication (prior VTE, or cancer)
17
12/15/2015
SVT Treatment: Bottom Line • How to treat? Arixtra 2.5 mg QD (prophy dose) Prophylactic does LMWH Novel Anticoagulant?
• How long to treat? 6 weeks
2012 ACCP Guidelines: Superficial Vein Thrombosis •Lower limb SVT ≥ 5 cm in length, we suggest prophylactic fondaparinux or LMWH for 45 days over no anticoagulation (Grade 2B). •We suggest fondaparinux 2.5 mg daily over prophylactic LMWH (Grade 2C).
ACCP Guidelines 2012
18
12/15/2015
Thanks
[email protected]
19